Science & Technology
Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1SB1CA302068-01
Award Ceiling
$249K
Award Floor
$249K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$249K
Expected Awards
1
Posted Date
Sep 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1SB1CA302068-01
Description
SBIR Phase Phase II award: "Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas" awarded to MYOSIN THERAPEUTICS INC in JUPITER, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $249,417. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.